PTP4A1 and systemic sclerosis: Considering that inducible systemic Ptp4a1 KO did not result in any clinically evident adverse effect in mice, the work described in this paper suggests that further validation of PTP4A1 as a selective drug target for SSc and potentially other fibrotic diseases might be warranted.